Evaluation in a mouse model of a thyroid-blocking protocol for 131I antibody therapy (short communication)

Cancer Biotherapy and Radiopharmaceuticals

Volumn 13, Issue 6, 1998, Pages 457-460

  Zuckier, Lionel S ^a   Li, Yi ^a   Chang, Chee J ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Antibodies; Iodide; Perchlorate; Radioimmunotherapy; Thyroid

Indexed keywords

IODINE 131; POTASSIUM IODIDE; POTASSIUM PERCHLORATE; RADIOACTIVE IODINE; SODIUM IODIDE I 131;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; EVALUATION; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; THYROID GLAND; WHOLE BODY SCINTISCANNING;

EID: 0032415603     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.1998.13.457     Document Type: Article

References (6)

1. DeNardo GL, O'Donnell RT, Oldham RK, DeNardo SJ. A revolution in the treatment of non-Hodgkin's lymphoma. Cancer Biother Radiopharm 1998; 13:213-223.
2. 131I-Lym-1. Cancer Res (Suppl) 1990; 50: 1014s-1016s.
3. Goldenberg DM, Horowitz JA, Sharkey RM, et al.Targeting, dosimetry,and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody. J Clin Oncol 1991; 9: 548-564.
4. Juweid M, Sharkey RM, Markowitz A, Behr T, Swayne LC, Dunn R, Hansen HJ, et al. Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody. Cancer Res (Suppl) 1995; 55: 5899s-5907s.
5. Kaminski MS, Zasadny KR, Francis IR, Fenner MC, Ross CW, Milik AW, Estes J, et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 1996;14:1974-1981.
6. SAS system for mixed models. SAS Institute, Inc. 1968.